Brokerages Set Lantheus Holdings, Inc. (NASDAQ:LNTH) Target Price at $131.86

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have covered the stock in the last year is $131.86.

Several research analysts have recently weighed in on LNTH shares. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. Truist Financial reiterated a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday.

Lantheus Price Performance

Lantheus stock opened at $91.58 on Tuesday. The firm has a market capitalization of $6.37 billion, a PE ratio of 15.24 and a beta of 0.46. The company’s 50-day moving average is $89.64 and its 200-day moving average is $99.77. Lantheus has a fifty-two week low of $50.20 and a fifty-two week high of $126.89.

Institutional Trading of Lantheus

A number of institutional investors have recently bought and sold shares of the business. UMB Bank n.a. boosted its holdings in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the period. Shelton Wealth Management LLC boosted its holdings in Lantheus by 77.8% in the 4th quarter. Shelton Wealth Management LLC now owns 11,969 shares of the medical equipment provider’s stock valued at $1,071,000 after purchasing an additional 5,237 shares during the period. Procyon Advisors LLC boosted its holdings in Lantheus by 11.1% in the 4th quarter. Procyon Advisors LLC now owns 3,613 shares of the medical equipment provider’s stock valued at $323,000 after purchasing an additional 361 shares during the period. Empirical Asset Management LLC bought a new stake in Lantheus in the 4th quarter valued at about $323,000. Finally, Park Avenue Securities LLC boosted its holdings in Lantheus by 26.4% in the 4th quarter. Park Avenue Securities LLC now owns 2,458 shares of the medical equipment provider’s stock valued at $220,000 after purchasing an additional 513 shares during the period. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.